Skip to main content
Top
Published in: Osteoporosis International 8/2015

01-08-2015 | Position Paper

FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK

Authors: E. McCloskey, J. A. Kanis, H. Johansson, N. Harvey, A. Odén, A. Cooper, C. Cooper, R. M. Francis, D. M. Reid, D. Marsh, P. Selby, F. Thompson, S. Hewitt, J. Compston

Published in: Osteoporosis International | Issue 8/2015

Login to get access

Abstract

Summary

Under current guidelines, based on prior fracture probability thresholds, inequalities in access to therapy arise especially at older ages (≥70 years) depending on the presence or absence of a prior fracture. An alternative threshold (a fixed threshold from the age of 70 years) reduces this disparity, increases treatment access and decreases the need for bone densitometry.

Introduction

Several international guidelines set age-specific intervention thresholds at the 10-year probability of fracture equivalent to a woman of average BMI with a prior fracture. At older ages (≥70 years), women with prior fracture selected for treatment are at lower average absolute risk than those selected for treatment in the absence of prior fracture, prompting consideration of alternative thresholds in this age group.

Methods

Using a simulated population of 50,633 women aged 50–90 years in the UK, with a distribution of risk factors similar to that in the European FRAX derivation cohorts and a UK-matched age distribution, the current NOGG intervention and assessment thresholds were compared to one where the thresholds remained constant from 70 years upwards.

Results

Under current thresholds, 45.1 % of women aged ≥70 years would be eligible for therapy, comprising 37.5 % with prior fracture, 2.2 % with high risk but no prior fracture and 5.4 % selected for treatment after bone mineral density (BMD) measurement. Mean hip fracture probability was 11.3, 23.3 and 17.6 %, respectively, in these groups. Under the alternative thresholds, the overall proportion of women treated increased from 45.1 to 52.9 %, with 8.4 % at high risk but no prior fracture and 7.0 % selected for treatment after BMD measurement. In the latter group, the mean probability of hip fracture was identical to that observed in women with prior fracture (11.3 %). The alternative threshold also reduced the need for BMD measurement, particularly at older ages (>80 years).

Conclusions

The alternative thresholds equilibrate fracture risk, particularly hip fracture risk, in those with or without prior fracture selected for treatment and reduce BMD usage at older ages.
Literature
1.
go back to reference Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(23–57):23079689 Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(23–57):23079689
2.
go back to reference Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8(164):24390553 Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8(164):24390553
3.
go back to reference Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(392–396):23810490 Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(392–396):23810490
4.
go back to reference Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8(148):23975235 Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8(148):23975235
5.
go back to reference Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H, McCloskey E, Kanis JA (2012) The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Arch Osteoporos 7(229–235):23060308 Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H, McCloskey E, Kanis JA (2012) The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Arch Osteoporos 7(229–235):23060308
6.
go back to reference Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(2257–2276):22434203 Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(2257–2276):22434203
7.
go back to reference National Institute for Health and Care Excellence (2012) NICE Clinical Guideline 146. Osteoporosis: assessing the risk of fragility fracture National Institute for Health and Care Excellence (2012) NICE Clinical Guideline 146. Osteoporosis: assessing the risk of fragility fracture
8.
go back to reference Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(385–397):18292978 Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(385–397):18292978
9.
go back to reference Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344(e3427):22619194 Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344(e3427):22619194
10.
go back to reference Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(105–108):19135323 Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(105–108):19135323
11.
go back to reference Bruyere O, Fossi M, Zegels B, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33(973–978):22842952 Bruyere O, Fossi M, Zegels B, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33(973–978):22842952
12.
go back to reference Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(304–313):22521109 Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(304–313):22521109
13.
go back to reference Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(906–913):15190881 Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(906–913):15190881
14.
go back to reference Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23(907–915):22234810 Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23(907–915):22234810
15.
go back to reference NICE (2010) TA161 (amended) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence NICE (2010) TA161 (amended) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence
16.
go back to reference Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21(41–52):19705046 Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21(41–52):19705046
17.
go back to reference Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19(449–458):18292975 Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19(449–458):18292975
18.
go back to reference Hagino H (2014) Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis. Clin Calcium 24:11–18, 24369275 PubMed Hagino H (2014) Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis. Clin Calcium 24:11–18, 24369275 PubMed
19.
go back to reference Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(1395–1408):18751937 Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(1395–1408):18751937
20.
go back to reference Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(495–505):19565175 Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(495–505):19565175
21.
go back to reference Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23(811–820):21717247 Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23(811–820):21717247
Metadata
Title
FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK
Authors
E. McCloskey
J. A. Kanis
H. Johansson
N. Harvey
A. Odén
A. Cooper
C. Cooper
R. M. Francis
D. M. Reid
D. Marsh
P. Selby
F. Thompson
S. Hewitt
J. Compston
Publication date
01-08-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3176-0

Other articles of this Issue 8/2015

Osteoporosis International 8/2015 Go to the issue